EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Prevalence of Treatment‐Resistant Schizophrenia: A Nationwide Multicenter Study

Yusuke Arai iD, Toru Horinouchi iD, Hiroyuki Muraoka iD, Junya Matsumoto iD, Kazuhiko Yamamuro iD, Toshinori Nakamura iD, Hisashi Yamada iD, Toshiaki Onitsuka iD, Yuka Yasuda iD, Naoki Hashimoto, Kazutaka Ohi iD, Shinichiro Ochi iD und 12 weitere

Neuropsychopharmacology Reports · 2026

DOI: 10.1002/npr2.70163 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Neuropsychopharmacology Reports, 2026. Verfasst von Yusuke Arai und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Community Mental Health, Shinshu University School of Medicine, Matsumoto, Nagano, Japan. Hauptthemen laut MEDLINE: Schizophrenia, Treatment-Resistant, Antipsychotic Agents, Schizophrenia. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, JSPS KAKENHI, Health and Labor Sciences Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Schizophrenia is characterized by positive symptoms, negative symptoms, and cognitive impairment and is primarily treated with antipsychotic medications. However, a subset of patients responds inadequately to treatment and is classified as having treatment‐resistant schizophrenia (TRS). The prevalence of TRS among patients with schizophrenia remains insufficiently characterized. This study aimed to determine the prevalence of TRS using nationwide data and standardized diagnostic criteria.

Methods

This study included patients with schizophrenia who were discharged between 2016 and 2024 from 205 institutions participating in the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project and authorized to prescribe clozapine. TRS was defined according to standardized diagnostic criteria used in Japan. The prevalence of TRS was calculated among patients who underwent a TRS examination by their treating psychiatrist.

Results

Among 18 914 patients, 9870 (52.2%) underwent a TRS examination. Among these 9870 patients, 2819 were classified as having TRS, corresponding to a prevalence of 28.6%. Among the 2819 patients with TRS, 1307 were prescribed clozapine at discharge, corresponding to a clozapine treatment rate of 46.4%.

Conclusions

This study had the largest sample size among single‐cohort studies investigating the prevalence of TRS. The prevalence of TRS was 28.6% among patients with schizophrenia who underwent a TRS examination and was nearly identical to the pooled prevalence reported in studies at low risk of bias in a previous meta‐analysis. These findings may provide important evidence regarding the prevalence of TRS in routine clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Schizophrenia, Treatment-ResistantAntipsychotic AgentsSchizophreniaHumansPrevalenceFemaleMaleJapanClozapineAdultMiddle Aged

Stichwörter der Autor:innen

clozapineprevalenceschizophreniatreatment‐resistant schizophrenia

Substanzen

Antipsychotic AgentsClozapine

Autor:innen und Institutionen

  • Department of Community Mental Health, Shinshu University School of Medicine, Matsumoto, Nagano, Japan.
  • Department of Psychiatry and Neurology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
  • Department of Psychiatry, Kitasato University, School of Medicine, Sagamihara, Kanagawa, Japan.
  • Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
  • Center for Health Control, Nara Medical University, Kashihara, Nara, Japan.
  • Department of Psychiatry, Nara Medical University School of Medicine, Kashihara, Nara, Japan.

ORCID-Profile: Yusuke Arai, Toru Horinouchi, Hiroyuki Muraoka, Junya Matsumoto, Kazuhiko Yamamuro, Toshinori Nakamura, Hisashi Yamada, Toshiaki Onitsuka, Yuka Yasuda, Kazutaka Ohi, Shinichiro Ochi, Yasushi Kawamata, Keisuke Mori, Hirotaka Yamagata, Takashi Tsuboi, Fumitoshi Kodaka, Jun-Ichi Iga, Ken Inada, Koichiro Watanabe, Hikaru Hori, Norio Yasui-Furukori, Ryota Hashimoto

Förderung

  • Japan Agency for Medical Research and Development
  • JSPS KAKENHI
  • Health and Labor Sciences Research
  • Japanese Society of Mood Disorders
  • Japanese Society of Neuropsychopharmacology
  • Japanese Society of Clinical Neuropsychopharmacology
  • Japanese Society of Psychiatry and Neurology
  • Shinshu Association for the Advancement of Medical Sciences

Zitieren

APA

Arai, Y., Horinouchi, T., Muraoka, H., Matsumoto, J., Yamamuro, K., Nakamura, T., Yamada, H., Onitsuka, T., Yasuda, Y., Hashimoto, N., Ohi, K., Ochi, S., Kawamata, Y., Mori, K., Yamagata, H., Tsuboi, T., Kodaka, F., Iga, J. I., Numata, S., …, & Hashimoto, R. (2026). Prevalence of Treatment‐Resistant Schizophrenia: A Nationwide Multicenter Study. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.70163

Vancouver

Arai Y, Horinouchi T, Muraoka H, Matsumoto J, Yamamuro K, Nakamura T, et al. Prevalence of Treatment‐Resistant Schizophrenia: A Nationwide Multicenter Study. Neuropsychopharmacology Reports. 2026. doi:10.1002/npr2.70163

BibTeX
@article{Arai2026,
  author = {Arai, Yusuke and Horinouchi, Toru and Muraoka, Hiroyuki and Matsumoto, Junya and Yamamuro, Kazuhiko and Nakamura, Toshinori and Yamada, Hisashi and Onitsuka, Toshiaki and Yasuda, Yuka and Hashimoto, Naoki and Ohi, Kazutaka and Ochi, Shinichiro and Kawamata, Yasushi and Mori, Keisuke and Yamagata, Hirotaka and Tsuboi, Takashi and Kodaka, Fumitoshi and Iga, Jun-Ichi and Numata, Shusuke and Inada, Ken and Watanabe, Koichiro and Hori, Hikaru and Yasui-Furukori, Norio and Hashimoto, Ryota},
  title = {Prevalence of Treatment‐Resistant Schizophrenia: A Nationwide Multicenter Study},
  journal = {Neuropsychopharmacology Reports},
  year = {2026},
  doi = {10.1002/npr2.70163}
}
Kostenlos starten →